Additional file 9 of Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

Additional file 9: Supplementary Fig.5. Capmatinib inhibits MET downstream pathways and is effective against further MET driven pHGG models. a, Western blots showing the levels of phosphorylated MET kinase domain and pERK in response to crizotinib- or capmatinib-treatment after 30 min, 2 hours and 24 hours in TRIM24-MET-i and TRIM24-MET-r cells. cri=crizotinib, cap=capmatinib. b, Western blots showing the levels of pAKT in response to crizotinib- or capmatinib-treatment after 30min, 2 hours and 24 hours in TRIM24-MET-i and TRIM24-MET-r cells. cri=crizotinib, cap=capmatinib. c,d, Dose-response curves of indicated tumor cell cultures after treatment with capmatinib. Each dot or symbol represents one biological replicate of technical triplicates. Viable cells were analyzed 72 hours after compound addition using the CellTiter-Glo Assay.